Jump to: Page Content, Site Navigation, Site Search,
You are seeing this message because your web browser does not support basic web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.
BMJ 2007;334:1290 (23 June), doi:10.1136/bmj.39251.457315.4E
Ray Moynihan
Byron Bay, Australia
| The first 150 words of the full text of this article appear below. |
An international alliance of consumer groups, insurers, and professional associations has stepped up its attacks on the European Commission's current round of public consultation over drug advertising.
The EC released a report for public consultation earlier this year on current sources of patient information, and it is seeking public comment by the end of June. The report gives strong support to the idea of allowing drug companies to give more information directly to patients, a proposal that critics argue will undermine Europe's strict ban on direct to consumer drug advertising.
In an open letter sent to two commissioners last week, the alliance, which includes Health Action International, the Medicines in Europe Forum, and the International Society of Drug Bulletins, attacked the "shaky and undocumented nature of the commission's analysis and the resultant bias in its conclusions."
Specifically the alliance argues that the commission's report gives an incomplete list of currently
![]()
CiteULike
Complore
Connotea
Del.icio.us
Digg
Reddit
Technorati What's this?
Read all Rapid Responses
Israeli students are refusing to perform intimate examinations on anaesthetised women without their informed consent.